Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACARBOSE vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in individuals with impaired glucose tolerance
treatment of symptomatic benign prostatic hyperplasia (BPH),combination therapy for BPH
Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
Terminal elimination half-life is approximately 2.5 to 3 hours for the parent compound, but the drug acts locally in the GI tract; systemic half-life is not clinically relevant for its pharmacodynamic effect.
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Acarbose is metabolized exclusively within the gastrointestinal tract, primarily by intestinal bacteria and digestive enzymes. Approximately 35% of the dose is absorbed as metabolites, which are excreted via the kidneys. The parent drug is not significantly metabolized by hepatic enzymes.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5; tamsulosin is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
Primarily excreted unchanged in feces (approximately 50% of an oral dose) and as metabolites via the gastrointestinal tract; less than 2% of the dose is recovered in urine as active drug or metabolites. Renal excretion is minimal.
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Negligible to low protein binding; less than 1-2% bound to plasma proteins, primarily albumin.
Dutasteride: >99.5% bound to albumin and alpha-1-acid glycoprotein. Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Volume of distribution is not well defined due to minimal systemic absorption; estimated to be less than 0.3 L/kg, reflecting limited distribution beyond the gastrointestinal lumen.
Dutasteride: Vd 300-500 L (total body, large tissue distribution). Tamsulosin: Vd 0.2 L/kg (approx 14-30 L, moderate distribution).
Oral: Systemic bioavailability is very low (approximately 0.5-2%) due to local action in the GI tract and minimal absorption. The drug acts locally in the intestine; systemic levels are negligible.
Dutasteride: Oral bioavailability ~60% (enhanced with food). Tamsulosin: Oral bioavailability ~30% (increased with food; formulation designed for consistent absorption).
No specific dose adjustment required for GFR ≥25 m L/min; contraindicated in GFR <25 m L/min (creatinine clearance <25 m L/min).
No dosage adjustment is required for renal impairment. Tamsulosin is extensively metabolized and renally excreted as inactive metabolites; however, no specific GFR-based adjustments are recommended.
No specific dose adjustment for mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (Child-Pugh class C).
Dutasteride is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For mild to moderate hepatic impairment (Child-Pugh A or B), no dosage adjustment is recommended, but caution is advised.
Not recommended for use in pediatric patients; safety and efficacy not established.
Safety and efficacy in pediatric patients have not been established. Use is not recommended in patients under 18 years of age.
Initiate at the lowest dose (25 mg 3 times daily); titrate slowly based on tolerance and glycemic control, as elderly patients may have reduced renal function and higher risk of gastrointestinal adverse effects.
No specific dose adjustment is required based on age alone. Elderly patients may be more sensitive to orthostatic hypotension from tamsulosin; monitor blood pressure and advise caution when rising from a seated or lying position.
None
None
Risk of hepatotoxicity: rare cases of severe hepatocellular injury, including fulminant hepatitis, reported, especially at higher doses (≥300 mg/day); monitor liver enzymes periodically.,Use with caution in patients with renal impairment (e GFR <25 m L/min/1.73 m²): insufficient data; avoid use.,May cause hypoglycemia when used in combination with sulfonylureas or insulin; treat hypoglycemia with oral glucose (dextrose) rather than sucrose (acarbose inhibits sucrose digestion).,Gastrointestinal adverse effects (flatulence, diarrhea, abdominal pain) are common due to undigested carbohydrate fermentation in the colon; may subside with continued use.,Acute porphyria: acarbose has been associated with acute attacks in susceptible patients.
Orthostatic hypotension/syncope, especially with concurrent antihypertensives,Intraoperative floppy iris syndrome during cataract surgery,Risk of high-grade prostate cancer (increased Gleason score 8-10 with dutasteride),Hepatic impairment may increase exposure,Sexual dysfunction: decreased libido, erectile dysfunction, ejaculation disorders
Hypersensitivity to acarbose or any component of the formulation,Diabetic ketoacidosis,Cirrhosis or significant hepatic impairment,Inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Renal impairment (e GFR <25 m L/min/1.73 m²)
Hypersensitivity to dutasteride, tamsulosin, or other 5α-reductase inhibitors,Women who are or may become pregnant (risk of fetal harm due to androgen inhibition),Severe hepatic impairment (Child-Pugh Class C),History of orthostatic hypotension
Acarbose delays digestion of complex carbohydrates and sucrose. To reduce gastrointestinal side effects, avoid high-sucrose foods and drinks. Simple sugars like glucose and fructose can still be absorbed and used to treat hypoglycemia. Alcohol may increase the risk of hypoglycemia when combined with acarbose, especially if taken with other antidiabetic agents.
Absorption of tamsulosin is decreased when taken with food; however, the combination product should be taken 30 minutes after a meal to maintain consistent exposure. Avoid grapefruit juice as it may increase tamsulosin concentrations. No specific food interactions with dutasteride.
Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposure. Risk cannot be excluded in first trimester. Second and third trimester: no known fetal risks, but use only if clearly needed.
Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosin has no known teratogenic risk. First trimester: Dutasteride exposure may cause feminization of male fetuses. Second and third trimesters: Risk persists; avoid use.
Acarbose is excreted into breast milk in negligible amounts due to low oral bioavailability and high molecular weight. M/P ratio not established. Considered compatible with breastfeeding; monitor infant for gastrointestinal effects (e.g., flatulence, diarrhea).
Unknown if dutasteride or tamsulosin are excreted in human milk. Dutasteride is lipophilic and may appear in milk. Tamsulosin likely excreted. M/P ratio not available. Due to potential for adverse effects (e.g., hypotension), breastfeeding is not recommended during therapy.
No dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to minimal systemic absorption. Initiate at 25 mg three times daily with meals; titrate based on 1-hour postprandial glucose levels.
No dose adjustment studies in pregnancy. Dutasteride should not be used; tamsulosin is not recommended. No pharmacokinetic changes requiring dose adjustment are established, but avoid use.
Acarbose delays carbohydrate absorption by inhibiting alpha-glucosidase in the brush border of the small intestine. It should be taken with the first bite of each main meal. Its efficacy is limited by gastrointestinal side effects (flatulence, diarrhea) due to undigested carbohydrates reaching the colon. Not recommended in patients with inflammatory bowel disease or colonic obstruction. Hypoglycemia from acarbose (rare in monotherapy) must be treated with oral glucose or milk, not sucrose or complex carbohydrates, since their digestion is blocked. Acarbose can cause isolated transaminase elevations; monitor LFTs if symptoms occur.
Dutasteride/tamsulosin is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5α-reductase inhibitor that reduces prostate volume over months; tamsulosin is an α1-adrenoceptor antagonist providing rapid symptom relief. Do not split or crush capsules. Avoid use in women and children. Monitor for orthostatic hypotension, especially when initiating therapy. Assess for drug-drug interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dutasteride exposure; tamsulosin interacts with other α-blockers, antihypertensives, and PDE5 inhibitors. Counsel patients about risk of postural hypotension and syncope. Advise patients to avoid driving or hazardous activities until they know how the medication affects them. Dutasteride may cause sexual dysfunction (decreased libido, ejaculatory dysfunction, gynecomastia). Tamsulosin may cause intraoperative floppy iris syndrome during cataract surgery; inform ophthalmologist of use. Monitor serum PSA levels: dutasteride decreases PSA by ~50% after 6 months; establish new baseline. Do not use in patients with history of prostate cancer.
Take acarbose with the first bite of each main meal; do not take it between meals.,Common side effects include gas, bloating, and diarrhea, which may improve over time.,If you experience low blood sugar, treat it with glucose tablets, juice, or regular soda, not candy or fruit juice (acarbose blocks their digestion).,Tell your doctor if you develop jaundice or abdominal pain, as liver problems can occur.,This medication is not for weight loss and does not affect insulin secretion.
Take this medication once daily, 30 minutes after the same meal each day.,Swallow capsules whole; do not crush, chew, or open.,Rise slowly from sitting or lying down to avoid dizziness or fainting.,Avoid driving or operating machinery until you know how the drug affects you.,Inform your doctor if you plan to have cataract surgery, as this drug may cause complications.,Do not donate blood while taking this medication, as it may harm a fetus if given to a pregnant woman.,Women who are pregnant or may become pregnant should not handle crushed or broken capsules.,Report any breast lumps, pain, or nipple discharge, as gynecomastia is possible.,Use condoms if your partner is pregnant, as dutasteride can be absorbed through skin contact with semen.,Keep all appointments for PSA blood tests; the test result will be lower than expected.,Do not take other alpha-blocker medications for blood pressure or prostate problems while on this drug unless prescribed.,Grapefruit juice may increase side effects; limit or avoid consumption.,Do not stop taking this medication suddenly without consulting your doctor.
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the gut, leading to a reduction in postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity in some patients, potentially increasing the risk of hypoglycemia when combined with acarbose. The interaction is primarily due to additive effects on glucose metabolism, and patients should be monitored for signs of hypoglycemia, particularly during initiation or dose adjustments."
"Chlorothiazide, a thiazide diuretic, can decrease the therapeutic efficacy of acarbose, an alpha-glucosidase inhibitor used for postprandial glycemic control in type 2 diabetes. The hypokalemia induced by chlorothiazide may impair insulin secretion and reduce the glucose-lowering effect of acarbose, potentially leading to elevated postprandial glucose levels. This interaction may necessitate dose adjustments or alternative antihyperglycemic therapy to maintain glycemic control."
"Acarbose, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, thereby reducing postprandial hyperglycemia. Selegiline, a selective MAO-B inhibitor at therapeutic doses, can potentiate the hypoglycemic effect of acarbose by an unknown pharmacodynamic mechanism, potentially leading to episodes of hypoglycemia. This interaction is of particular concern in patients with diabetes mellitus who are co-prescribed these agents, as the combined effect on glucose homeostasis may require dose adjustments or enhanced monitoring."
"Tamsulosin, an alpha-1 adrenergic antagonist, and fosinopril, an ACE inhibitor, both lower blood pressure through distinct mechanisms, leading to additive hypotensive effects. This synergistic action increases the risk of orthostatic hypotension, dizziness, syncope, and falls, particularly at treatment initiation or dose escalation. The interaction is of clinical concern in elderly patients or those with volume depletion."
"Lofexidine, a central alpha-2 adrenergic agonist, reduces sympathetic outflow and can cause bradycardia and hypotension. Tamsulosin, an alpha-1 adrenergic receptor antagonist, also lowers blood pressure, especially orthostatic. Combined use leads to additive hypotensive effects, increasing risk of symptomatic bradycardia, orthostatic hypotension, syncope, and falls, particularly at therapy initiation or dose titration."
"The combination of tamsulosin and moexipril can lead to an increased risk of hypotension and orthostatic hypotension due to additive vasodilatory effects. Tamsulosin, an alpha-1 adrenergic antagonist, reduces peripheral vascular resistance, while moexipril, an ACE inhibitor, decreases angiotensin II production, further promoting vasodilation. This synergistic effect may cause symptomatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or during dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACARBOSE vs DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, answered by our medical review team.
ACARBOSE is a Alpha-Glucosidase Inhibitor that works by Acarbose is a complex oligosaccharide that competitively and reversibly inhibits α-glucosidase enzymes in the brush border of the small intestine. This delays the digestion and absorption of complex carbohydrates and disaccharides, thereby reducing postprandial hyperglycemia.. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACARBOSE and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACARBOSE is: Initial: 25 mg orally 3 times daily with first bite of each main meal; maintenance: 50-100 mg 3 times daily; max 100 mg 3 times daily.. The standard adult dose of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is: One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACARBOSE and DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACARBOSE is classified as Category C. Acarbose is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Minimal systemic absorption (<2%) suggests low fetal exposu. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is classified as Category A/B. Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.